While intratumoral CD8+ T-cells do not predict improved clinical outcome in HER2+ breast cancer, TBET+ tumor infiltrate predicted improved RFS (p = 0.04 HR 4.76, 95 % CI 1.07 to 20) in 102 HER2 tumors treated with trastuzumab [22]. This evidence concerns the gene CD8A and breast carcinoma.